Primary Site >> Stomach Cancer
Gene >> CYP2C19
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
|
Ref: Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population. PMID: 15222046 |
Ref: Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection. PMID: 16268979 Ref: Gastroduodenal disease, Helicobacter pylori, and genetic polymorphisms. PMID: 16361041 |
Ref: [Clinical use of proton pump inhibitors in gastrointestinal diseases]. PMID: 16554671 Ref: CYP2C19 polymorphisms in patients with gastric and colorectal carcinoma. PMID: 17290075 |
Ref: Poor metabolizers at the cytochrome P450 2C19 loci is at increased risk of developing cancer in Asian populations. PMID: 24015291 |
Ref: Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand. PMID: 25520127 Ref: Effects of the CYP2C19 genetic polymorphism on gastritis, peptic ulcer disease, peptic ulcer bleeding and gastric cancer. PMID: 25605208 |
Ref: Outcomes of a Randomized Controlled Trial Comparing Modified High Dose Omeprazole and Amoxicillin Triple Therapy with Standard Triple Therapy for Helicobacter Pylori Eradication PMID: 28545189 Ref: Effectiveness of 7-Day and 14-Day Moxifloxacin-Dexlansoprazole Based Triple Therapy and Probiotic Supplement for Helicobacter Pylori Eradication in Thai Patients with Non-Ulcer Dyspepsia: A Double-Blind Randomized Placebo-Controlled Study PMID: 29072432 |
Ref: Influence of SLCO1B1 in gastric cancer patients treated with EOF chemotherapy. PMID: 30214584 |